Mahana Therapeutics Selected for Prestigious Digitalhealth.London Accelerator Program
Retrieved on:
Tuesday, January 18, 2022
Mental Health, Health, Technology, Other Health, Software, Pharmaceutical, Biotechnology, CE marking, Ministry, Patient, European Regional Development Fund, Accelerator, Technology, CBT, Union, ERDF, Pan-Mass Challenge, Adoption, Community, CW, Population, Mass, Solution, NHS, Irritable bowel syndrome, Health, Ministry of Housing, Communities and Local Government, Cognitive behavioral therapy, SME, Therapy, Program, Greater London Authority, MedCity, European Structural and Investment Funds, Multimedia, NHSX, Local government, IBS, FDA, Economic development, UCLPartners, Pharmaceutical industry, Health insurance, Housing, Mahana Therapeutics, DigitalHealth.London Accelerator, European Regional Development Fund, MAHANA THERAPEUTICS, DIGITALHEALTH.LONDON ACCELERATOR, EUROPEAN REGIONAL DEVELOPMENT FUND
Mahana Therapeutics , a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.Londons Accelerator programme .
Key Points:
- Mahana Therapeutics , a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.Londons Accelerator programme .
- The program will help Mahana Therapeutics better engage with the NHS to accelerate adoption of Mahana IBS in clinical practice.
- We are excited to join this prestigious program to accelerate adoption of and experience with Mahana IBS within the NHS.
- Mahana Therapeutics is a leading developer of effective prescription digital therapeutics that are designed to empower patients with chronic conditions to live fuller lives.